Correspondence to letter to the editor on “Clinical significance of gross morphological type beyond tumor burden in hepatocellular carcinoma treated with atezolizumab plus bevacizumab”
Clinical and Molecular Hepatology · 05.11.2026
DOI: 10.3350/cmh.2026.1191 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical and Molecular Hepatology, online erschienen am 05.11.2026. Verfasst von Seonjeong Woo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science, CHA University, Seongnam, Republic of Korea.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Life Science, CHA University, Seongnam, Republic of Korea.
- Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.
- Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea. minidoctor@cha.ac.kr.
Zitieren
APA
Woo, S., Kim, D., Lee, W. S., & Chon, H. J. (2026). Correspondence to letter to the editor on “Clinical significance of gross morphological type beyond tumor burden in hepatocellular carcinoma treated with atezolizumab plus bevacizumab”. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2026.1191
Vancouver
Woo S, Kim D, Lee WS, Chon HJ. Correspondence to letter to the editor on “Clinical significance of gross morphological type beyond tumor burden in hepatocellular carcinoma treated with atezolizumab plus bevacizumab”. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2026.1191
BibTeX
@article{Woo2026,
author = {Woo, Seonjeong and Kim, Donghyeon and Lee, Won Suk and Chon, Hong Jae},
title = {Correspondence to letter to the editor on “Clinical significance of gross morphological type beyond tumor burden in hepatocellular carcinoma treated with atezolizumab plus bevacizumab”},
journal = {Clinical and Molecular Hepatology},
year = {2026},
doi = {10.3350/cmh.2026.1191}
}
EUVIMED